Differential effects of oral and intravenous lipid administration on key molecules related to energy homeostasis

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 5, 2016, Pages 1989-1997

  Vamvini, Maria T ^a,b   Hamnvik, Ole Petter ^a,c   Sahin Efe, Ayse ^a   Gavrieli, Anna ^a   Dincer, Fadime ^a   Farr, Olivia M ^a   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT AUBURN HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C PEPTIDE; FATTY ACID; FETUIN A; FIBROBLAST GROWTH FACTOR 21; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; IRISIN; LEPTIN; LIPID; OMENTIN; PEPTIDE YY; UNCLASSIFIED DRUG; CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; FNDC5 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ADMINISTRATION ROUTE; ENERGY HOMEOSTASIS; FEMALE; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN METABOLISM; MALE; OBESITY; PRIORITY JOURNAL; BLOOD; DRUG EFFECTS; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADIPONECTIN; ADMINISTRATION, ORAL; ADULT; ALPHA-2-HS-GLYCOPROTEIN; BLOOD GLUCOSE; C-PEPTIDE; CYTOKINES; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; FEMALE; FIBROBLAST GROWTH FACTORS; FIBRONECTINS; GHRELIN; GLUCAGON; GPI-LINKED PROTEINS; HOMEOSTASIS; HUMANS; INCRETINS; INFUSIONS, INTRAVENOUS; INSULIN; LECTINS; LIPIDS; MALE; MIDDLE AGED; PEPTIDE YY; YOUNG ADULT;

EID: 84969752620     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-4141     Document Type: Article

References (39)

1. Oprescu AI, Bikopoulos G, Naassan A, et al. Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo. Diabetes. 2007;56:2927-2937.
2. Boden G, Chen X, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes. 1995;44: 1239-1242.
3. Kusminski CM, Shetty S, Orci L, Unger RH, Scherer PE. Diabetes and apoptosis: lipotoxicity. Apoptosis. 2009;14:1484-1495.
4. Lindgren O, Carr RD, Deacon CF, et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab. 2011;96:2519-2524.
5. Robertson MD, Henderson RA, Vist GE, Rumsey RD. Plasma ghrelin response following a period of acute overfeeding in normal weight men. Int J Obes Relat Metab Disord. 2004;28:727-733.
6. Fernandez-Garcia JC, Murri M, Coin-Araguez L, Alcaide J, El Bekay R, Tinahones FJ. GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects. Clin Endocrinol (Oxf). 2014;80:671-676.
7. Duca FA, Sakar Y, Covasa M. The modulatory role of high fat feeding on gastrointestinal signals in obesity. J Nutr Biochem. 2013; 24:1663-1677.
8. Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol. 2009;587:27-32.
9. Khoury DE, Hwalla N, Frochot V, Lacorte JM, Chabert M, Kalopissis AD. Postprandial metabolic and hormonal responses of obese dyslipidemic subjects with metabolic syndrome to test meals, rich in carbohydrate, fat or protein. Atherosclerosis. 2010;210:307-313.
10. Mai K, Bobbert T, Groth C, et al. Physiological modulation of circulating FGF21: relevance of free fatty acids and insulin. Am J Physiol Endocrinol Metab. 2010;299:E126-E130.
11. Yu H, Xia F, Lam KS, et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem. 2011;57:691-700.
12. Sanchez J, Nozhenko Y, Palou A, Rodriguez AM. Free fatty acid effects on myokine production in combination with exercise mimetics. Mol Nutr Food Res. 2013;57:1456-1467.
13. Panagiotou G, Mu L, Na B, Mukamal KJ, Mantzoros CS. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism. 2014;63:1265-1271.
14. Foo JP, Aronis KN, Chamberland JP, Paruthi J, Moon HS, Mantzoros CS. Fibroblast growth factor 21 levels in young healthy females display day and night variations and are increased in response to short-term energy deprivation through a leptin-independent pathway. Diabetes Care. 2013;36:935-942.
15. Bluher S, Panagiotou G, Petroff D, et al. Effects of a 1-year exercise and lifestyle intervention on irisin, adipokines, and inflammatory markers in obese children. Obesity (Silver Spring). 2014;22:1701-1708.
16. Liu X, Hamnvik OP, Chamberland JP, et al. Circulating alanine transaminase (ALT) and gamma-glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus Metabolism Study. Metabolism. 2014;63:773-782.
17. Hamnvik OP, Thakkar B, Chamberland J, Aronis K, Schneider B, Mantzoros CS. Omentin-1 levels are reduced by pharmacologic doses of leptin, but remain unaffected by energy deprivation and display no day-night variation. Int J Obes (Lond). 2015;39: 260-264.
18. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012;61:1725-1738.
19. Foo JP, Aronis KN, Chamberland JP, Mantzoros CS. Lack of day/ night variation in fibroblast growth factor 21 levels in young healthy men. Int J Obes (Lond). 2015;39:945-948.
20. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest. 1995;95:2195-2204.
21. Kim YB, Uotani S, Pierroz DD, Flier JS, Kahn BB. In vivo administration of leptin activates signal transduction directly in insulinsensitive tissues: overlapping but distinct pathways from insulin. Endocrinology. 2000;141:2328-2339.
22. Carstensen M, Thomsen C, Hermansen K. Incremental area under response curve more accurately describes the triglyceride response to an oral fat load in both healthy and type 2 diabetic subjects. Metabolism. 2003;52:1034-1037.
23. Saisho Y. β-Cell dysfunction: its critical role in prevention and management of type 2 diabetes. World J Diabetes. 2015;6:109-124.
24. Gravena C, Mathias PC, Ashcroft SJ. Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. J Endocrinol. 2002;173:73-80.
25. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297:127-136.
26. Christensen M, Vedtofte L, Holst JJ, Vilsboll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60:3103-3109.
27. Lindgren O, Pacini G, Tura A, Holst JJ, Deacon CF, Ahren B. Incretin effect after oral amino acid ingestion in humans. J Clin Endocrinol Metab. 2015;100:1172-1176.
28. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): part I. Distribution, release and actions. Obes Surg. 2006;16:651-658.
29. Mittelman SD, Klier K, Braun S, Azen C, Geffner ME, Buchanan TA. Obese adolescents show impaired meal responses of the appetite-regulating hormones ghrelin and PYY. Obesity (Silver Spring). 2010;18:918-925.
30. Van Name M, Giannini C, Santoro N, et al. Blunted suppression of acyl-ghrelin in response to fructose ingestion in obese adolescents: the role of insulin resistance. Obesity (Silver Spring). 2015;23: 653-661.
31. Chan JL, Wong SL, Mantzoros CS. Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity. Clin Pharmacokinet. 2008;47:753-764.
32. Asrih M, Jornayvaz FR. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol Cell Endocrinol. 2015;418(Pt 1):55-65.
33. Stefan N, Haring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol. 2013;9:144-152.
34. Arafat AM, Kaczmarek P, Skrzypski M, et al. Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia. 2013;56:588-597.
35. Matikainen N, Taskinen MR, Stennabb S, et al. Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. Eur J Endocrinol. 2012;166:487-492.
36. Trepanowski JF, Mey J, Varady KA. Fetuin-A: a novel link between obesity and related complications. Int J Obes (Lond). 2015;39:734-741.
37. Eckardt K, Gorgens SW, Raschke S, Eckel J. Myokines in insulin resistance and type 2 diabetes. Diabetologia. 2014;57:1087-1099.
38. Vu A, Sidhom MS, Bredbeck BC, Kosmiski LA, Aquilante CL. Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease. Diabetol Metab Synd. 2014;6:4.
39. Feng WH, Yuan XW, Tong GY, et al. Correlated increase of omentin-1 and adiponectin by exenatide, avandamet and dietary change in diet-induced obese rats. Folia Biol. 2013;59:217-224.